ProPhase Labs (PRPH) announced the formation of its Clinical Science Advisory Board to support the clinical adoption and commercialization of its breakthrough BE-Smart molecular test for esophageal disease. The advisory board will provide expert strategic guidance as ProPhase leads the regulatory and commercialization pathway for BE-Smart, with the goal of establishing a new clinical and economic standard in the early detection and management of esophageal cancer risk. The advisory board includes Dr. Joe Abdo, the inventor of the BE-Smart test and a nationally recognized leader in molecular oncology. Also joining the advisory board is James McCullough, founder and CEO of Renalytix. Additional key opinion leaders and experts in the field will be added to the advisory board in the near future as the Company plans for its initial commercial launch.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRPH:
- ProPhase Labs’ Earnings Call: Strategic Moves Amid Challenges
- ProPhase Labs Reports Q1 2025 Earnings and Strategic Developments
- ProPhase Labs says CEO voluntarily agrees to defer salary by over two thirds
- ProPhase Labs expects to receive 6-month extension for Nasdaq listing
- ProPhase Labs moves forward with sale of Nebula Genomics